---
title: "Intensity Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285658875.md"
datetime: "2026-05-08T03:36:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285658875.md)
  - [en](https://longbridge.com/en/news/285658875.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285658875.md)
---

# Intensity Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.96, beating the estimate of USD -1.1067.

EBIT: As of FY2026 Q1, the actual value is USD -2.62 M.

### Financial Performance for Three Months Ended March 31, 2026

#### Net Loss

Intensity Therapeutics, Inc. reported a net loss of - $2.4 million for the three months ended March 31, 2026, which is an improvement compared to a net loss of - $3.3 million for the same period in 2025.

#### Loss from Operations

The loss from operations was - $2.526 million for the three months ended March 31, 2026, compared to - $3.394 million for the same period in 2025.

### Operating Expenses

#### Research and Development Expenses

Research and Development expenses were $1.2 million for the three months ended March 31, 2026, decreasing from $2.2 million for the same period in 2025, primarily due to lower INVINCIBLE-3 Study costs.

#### General and Administrative Expenses

General and Administrative expenses increased to $1.3 million for the three months ended March 31, 2026, from $1.2 million for the same period in 2025, mainly due to an estimated bonus accrual in 2026, partially offset by lower stock-based compensation and one-time expenses related to a reverse stock split.

#### Total Operating Expenses

Total operating expenses were $2.526 million for the three months ended March 31, 2026, down from $3.394 million for the same period in 2025.

### Other Financial Items

#### Interest Income

Interest income significantly increased to $94 thousand for the three months ended March 31, 2026, from $15 thousand in the prior year period.

#### Other (Expense) Income, Net

This category showed a net expense of - $2 thousand for the three months ended March 31, 2026, compared to a net income of $32 thousand for the same period in 2025.

### Balance Sheet Highlights

#### Cash and Cash Equivalents

As of March 31, 2026, cash and cash equivalents totaled $10.2 million, a decrease from $11.921 million as of December 31, 2025.

#### Total Current Assets

Total current assets were $10.906 million as of March 31, 2026, down from $12.709 million as of December 31, 2025.

#### Total Liabilities

Total liabilities increased slightly to $2.312 million as of March 31, 2026, from $2.225 million as of December 31, 2025.

### Operational Metrics and Outlook

#### INVINCIBLE-4 Study (Triple Negative Breast Cancer)

Preliminary observations from the INVINCIBLE-4 Study showed that 71.4% (5 out of 7) of patients in Cohort A (receiving INT230-6 prior to standard of care) achieved a pathological complete response (pCR), compared to 33% (2 out of 6) in Cohort B (standard of care alone). Cohort A also experienced 44% fewer grade 3 or higher adverse events than Cohort B.

#### INVINCIBLE-3 Study (Soft Tissue Sarcoma)

Intensity Therapeutics, Inc. plans to resume enrollment in a limited number of U.S. sites for the INVINCIBLE-3 Study by the third quarter of 2026, with full patient enrollment and site activations prioritized once sufficient incremental funding is obtained.

#### Outlook Summary

Intensity Therapeutics, Inc. plans to resume enrollment for the INVINCIBLE-4 Study in the second quarter of 2026, with initiation of enrollment in France expected in the second or third quarter of 2026, and for the INVINCIBLE-3 Study in limited U.S. sites by the third quarter of 2026, prioritizing full enrollment upon sufficient funding. More detailed results for INVINCIBLE-4 Cohort A are anticipated at a future oncology conference. The company also intends to judiciously manage its cash burn.

### Related Stocks

- [INTS.US](https://longbridge.com/en/quote/INTS.US.md)

## Related News & Research

- [AT&T announces Q2 2026 distribution of R$ 0.31 per unit, payable Aug. 12](https://longbridge.com/en/news/294826269.md)
- [TransUnion declares Q2 2026 dividend of $0.125 per share](https://longbridge.com/en/news/295092792.md)
- [VGP to host webcast on H1 2026 results](https://longbridge.com/en/news/295056101.md)
- [Grupo Clarin schedules webcast to discuss second-quarter 2026 results](https://longbridge.com/en/news/294738587.md)
- [Mobilezone schedules investor video conference on H1 2026 results](https://longbridge.com/en/news/294935560.md)